VIDEO: ADAURA results ‘practice changing’ for lung cancer
CHICAGO — Healio spoke with Karen L. Reckamp, MD, on updated findings from the ADAURA trial presented at ASCO Annual Meeting.
“The biggest practice-changing presentation was from the ADAURA trial, which is adjuvant osimertinib [(Tagrisso, AstraZeneca)] versus standard-of-care for patients who have EGFR-mutated non-small cell lung cancer status post-resection, stage IB through IIIA,” Reckamp, professor in medicine and director of the division of medical oncology at Cedars-Sinai Medical Center, said. “This was presented back in 2020 with improvement in disease-free survival, and this year the overall survival was presented and showed a significant improvement in overall survival in patients who had resected EGFR NSCLC.”
She said researchers observed the same benefit regardless of whether or not patients had received chemotherapy before receiving 3 years of osimertinib.
“This is clearly practice-changing and improved the overall survival rate for these patients who received osimertinib as adjuvant therapy,” Reckamp said.
Collapse
Healio Interview
Read more about